Business Standard

Covaxin: Bharat Biotech's Covid vaccine candidate gets Phase 3 trials nod

In a statement published on its website, the panel said it recommended granting the approval after studying the firm's Phase I and II data along with 'animal challenge data in two species'

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

The Hyderabad-based vaccine maker had applied to the DCGI on October 2

BS Web Team New Delhi
Drugs Controller General of India (DCGI's) Expert Committee has given its nod to Phase III clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin.

In a statement published on its website, the panel said it recommended granting the approval after studying the firm's Phase I and II data along with 'animal challenge data in two species'.

"After detailed deliberation and based on the available evidences, the committee recommended for grant of permission to conduct Phase III clinical trial," the statement reads. 

It, however, notes that the approval is subject to the condition that the primary efficacy endpoint for symptomatic cases should

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in